Follow $NIKI

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $NIKI by email
NASDAQ NMS - GLOBAL MARKET · NIKI
-0.15% · -$0.0101 · Vol 31.3K
Market closed · last close 4:00 PM ET · price as of 15:59:08 ET
Aptorum Group Ltd

Aptorum Group Ltd

Biotechnology
$6.61
Card
Relationship Map

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
NIKI
Aptorum Group Ltd
Thu Sep 3 · market closed · Markets closed · resumes Thu 9:30 ET
Middle range

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

48/ 100
Veridion Score
Middle range · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4 of 6 factors measured · Thu Sep 3 · market closed · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is NIKI moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading NIKI catalysts
About Aptorum Group Ltd
Biotechnology
Listed since
2018
Employees
2
Country
GB

Niki BioSolutions Inc, formerly Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA).

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$7.16
Day high
$7.29
Day low
$6.55
Previous close
$6.62
52W high
$10.17
-35.00% from high
52W low
$6.55
2% of range
Market cap
$5.4M
EPS
$-3.5373
Beta
2.33
Shares out
814.4K
Volume
31.3K
0.24× rel vol
Avg volume
132.3K
VWAP
$6.72
Price history computed in-house
1W
-12.33%
1M
-31.86%
SMA 50 Not reported · Not reported
SMA 200 Not reported · Not reported
52W position 2%

NIKI overview

Veridion Score
48
Registered · 2026-09-02
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around NIKI.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading NIKI Form 4 filings
Public disclosures

Congress activity in NIKI

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for NIKI in the cached public ledger.

Federal contracts

NIKI contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NIKI in this window.
Lobbying spend

NIKI lobbying filings, year to date.

Registered lobbying filings matched to Aptorum Group Ltd.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NIKI in this window.
Loading news for NIKI
Analyst ratings
Sovereign unlock shows live analyst consensus for NIKI.
Options
Sovereign unlock shows live options positioning for NIKI.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.